7 December 2025 — Today marks the five-year anniversary of id.DRIVE, a milestone that reflects half a decade of commitment to strengthening Europe’s infectious disease surveillance and post-marketing vaccine effectiveness assessment.
Launched on 7 December 2020 as COVIDRIVE, the initiative was created at the height of the COVID-19 pandemic to provide rapid, high-quality evidence on brand-specific COVID-19 vaccine effectiveness. Over time, the study framework broadened its scope, evolving into id.DRIVE in 2024, a comprehensive platform dedicated to infectious diseases and vaccine research beyond COVID-19.
A growing, impactful network
In just five years, id.DRIVE has achieved remarkable impact:
- 30,000+ SARI patients recruited,
- 6 brand-specific VE studies, 1 surveillance of respiratory viruses study,
- across 7 European countries in a network of 39 participating hospitals.
Our study network forms a robust, high-quality research infrastructure capable of producing regulatory-grade real-world evidence on the circulation of respiratory viruses and vaccine effectiveness. By harmonising data collection across countries and fostering a sustainable, cost-effective model, id.DRIVE has become a central resource for infectious disease research and surveillance in Europe.
A proven model for Public–Private collaboration
id.DRIVE is built on an public–private partnership model, bringing together expertise from across sectors. Over the years, the consortium has collaborated with 13 partners from both public institutions and private industry, working collectively to address shared public health priorities.
This collaborative approach has positioned id.DRIVE as a pivotal platform for brand-specific post-marketing studies, enabling timely, reliable, and comparable evidence generation across multiple pathogens and healthcare settings.
Looking ahead
As id.DRIVE enters its next phase, its commitment remains clear: to support public health with a sustainable, scalable, and trusted research platform capable of responding to current and emerging infectious disease threats.
The id.DRIVE consortium extends its gratitude to all partners, investigators, and patients who have contributed to the project’s success over the past five years. Together, we look forward to continuing to build a safer future for public health in Europe… and beyond.
